Vbi Vaccines Inc buy melinda
Start price
10.08.18
/
50%
?1.81
Target price
01.10.18
€2.62
Performance (%)
24.38%
End price
01.10.18
€2.26
Summary
This prediction ended on 01.10.18 with a price of €2.26. The prediction had a final performance of 24.38%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Vbi Vaccines Inc | - | - | - | - |
iShares Core DAX® | 1.851% | 5.158% | 17.711% | 19.954% |
iShares Nasdaq 100 | 1.573% | 2.589% | 39.053% | 56.636% |
iShares Nikkei 225® | -0.412% | -2.857% | 13.501% | 7.721% |
iShares S&P 500 | 1.128% | 2.485% | 29.871% | 47.507% |
Comments by melinda for this prediction
In the thread Vbi Vaccines Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
Develops biopharmaceuticals
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology.
Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine.
The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology.
Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine.
The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Nombre d'employés : 103 personnes.
(Vom Mitglied beendet)